Free Trial

Septerna (SEPN) Competitors

Septerna logo
$13.53 +1.06 (+8.50%)
Closing price 07/23/2025 04:00 PM Eastern
Extended Trading
$13.55 +0.02 (+0.15%)
As of 05:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SEPN vs. DNLI, BEAM, KNSA, BLTE, CNTA, VCEL, IRON, HRMY, IDYA, and CGON

Should you be buying Septerna stock or one of its competitors? The main competitors of Septerna include Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Kiniksa Pharmaceuticals International (KNSA), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Vericel (VCEL), Disc Medicine (IRON), Harmony Biosciences (HRMY), IDEAYA Biosciences (IDYA), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry.

Septerna vs. Its Competitors

Septerna (NASDAQ:SEPN) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

In the previous week, Denali Therapeutics had 2 more articles in the media than Septerna. MarketBeat recorded 2 mentions for Denali Therapeutics and 0 mentions for Septerna. Denali Therapeutics' average media sentiment score of 0.77 beat Septerna's score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Septerna Neutral
Denali Therapeutics Positive

Septerna currently has a consensus price target of $26.75, suggesting a potential upside of 97.71%. Denali Therapeutics has a consensus price target of $33.71, suggesting a potential upside of 132.99%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than Septerna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Septerna
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Denali Therapeutics
0 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
2 Strong Buy rating(s)
3.06

92.9% of Denali Therapeutics shares are held by institutional investors. 4.3% of Septerna shares are held by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Septerna's return on equity of 0.00% beat Denali Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SepternaN/A N/A N/A
Denali Therapeutics N/A -35.90%-32.41%

Septerna has higher earnings, but lower revenue than Denali Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Septerna$1.08M558.24-$71.80MN/AN/A
Denali Therapeutics$330.53M6.36-$422.77M-$2.67-5.42

Summary

Denali Therapeutics beats Septerna on 9 of the 13 factors compared between the two stocks.

Get Septerna News Delivered to You Automatically

Sign up to receive the latest news and ratings for SEPN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SEPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SEPN vs. The Competition

MetricSepternaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$555.64M$2.99B$5.58B$9.42B
Dividend YieldN/A2.44%4.05%3.99%
P/E RatioN/A21.2528.1520.08
Price / Sales558.24253.30398.5583.94
Price / CashN/A41.9636.1958.45
Price / Book1.438.198.595.83
Net Income-$71.80M-$55.10M$3.24B$258.27M
7 Day Performance7.21%5.56%3.51%2.69%
1 Month Performance26.33%18.19%10.96%12.91%
1 Year PerformanceN/A7.32%35.08%21.81%

Septerna Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SEPN
Septerna
1.1509 of 5 stars
$13.53
+8.5%
$26.75
+97.7%
N/A$555.64M$1.08M0.00N/A
DNLI
Denali Therapeutics
4.2113 of 5 stars
$14.69
+1.2%
$33.71
+129.5%
-39.4%$2.13B$330.53M-5.50430Upcoming Earnings
Gap Up
BEAM
Beam Therapeutics
2.0791 of 5 stars
$21.17
+0.0%
$48.75
+130.3%
-26.9%$2.13B$63.52M-4.59510Analyst Upgrade
Analyst Revision
KNSA
Kiniksa Pharmaceuticals International
3.4575 of 5 stars
$28.80
+2.5%
$39.33
+36.6%
+3.2%$2.10B$423.24M-115.20220Positive News
Analyst Forecast
BLTE
Belite Bio
1.7539 of 5 stars
$63.58
+0.6%
$96.67
+52.0%
+24.4%$2.02BN/A-46.7510Negative News
Gap Up
High Trading Volume
CNTA
Centessa Pharmaceuticals
3.3587 of 5 stars
$15.13
+4.9%
$27.89
+84.3%
+57.8%$2.02B$15M-8.36200Analyst Forecast
Insider Trade
High Trading Volume
VCEL
Vericel
3.8531 of 5 stars
$39.82
-0.3%
$61.14
+53.5%
-23.7%$2.00B$238.54M1,327.78300Positive News
Upcoming Earnings
IRON
Disc Medicine
3.3787 of 5 stars
$57.74
+1.5%
$96.70
+67.5%
+32.1%$2.00BN/A-14.7330Analyst Forecast
HRMY
Harmony Biosciences
4.8492 of 5 stars
$34.71
+2.1%
$51.33
+47.9%
+11.1%$1.99B$714.73M13.25200Positive News
Analyst Forecast
Analyst Revision
IDYA
IDEAYA Biosciences
4.2453 of 5 stars
$22.58
+0.4%
$47.55
+110.6%
-44.9%$1.98B$7M-6.2980News Coverage
Analyst Forecast
CGON
CG Oncology
2.4815 of 5 stars
$25.90
-3.1%
$56.80
+119.3%
-23.3%$1.97B$1.14M-17.1561Gap Up

Related Companies and Tools


This page (NASDAQ:SEPN) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners